153 results on '"Seghatchian, Jerard"'
Search Results
2. Spotlights on the trends in performance assessment of qualitative in vitro diagnostic medical devices in transfusion medicine
3. Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient’s safety and survival outcome:A systematic narrative appraisal of where we are now!
4. Cryopreservation of apheresis platelets treated with riboflavin and UV light
5. Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes
6. Blood transfusion in autoimmune rheumatic diseases
7. Spotlights on the latest opinions on identification, prevention, and management of newer CoV-2 variants: A roundup appraisal on innovative ideas and designer vaccines for Omicron
8. SARS-CoV-2 and cancer: the intriguing and informative cross-talk
9. Platelet and extracellular vesicles in COVID-19 infection and its vaccines
10. Assessment of extracellular vesicles using IFC for application in transfusion medicine
11. Trends and targets of various types of stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
12. An Overview of Current Position on Cell Therapy in Transfusion Science and Medicine: From Fictional Promises to Factual and Perspectives from Red Cell Substitution to Stem Cell Therapy
13. Update on newer approaches to prevent or treat COVID-19 infection: What we all need the most right now!!
14. An update on COVID-19 infection control measures, plasma-based therapeutics, corticosteroid pharmacotherapy and vaccine research
15. In vitro platelet production for transfusion purposes: Where are we now?
16. Spotlight on the current perspectives on applications of human blood cell culture and organoids: Introductory remarks
17. Cell culture – Fact and fiction
18. Covid-19, induced activation of hemostasis, and immune reactions: Can an auto-immune reaction contribute to the delayed severe complications observed in some patients?
19. When I need you most: frozen red blood cells for transfusion
20. Optimizing the supply of whole blood-derived bioproducts through the combined implementation of cryopreservation and pathogen reduction technologies and practices: An overview
21. Poor economics - Transforming challenges in transfusion medicine and science into opportunities
22. Platelet-derived bio-products: Classification update, applications, concerns and new perspectives
23. Plasma fractionation in countries with limited infrastructure and low-/medium income: How to move forward?
24. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA)
25. Platelet rich plasma in treatment of musculoskeletal pathologies
26. Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past
27. Optimal use of blood and innovative approaches to stem cells, regenerative medicine and donor recruitment
28. Reflections on the current position and future trends in immunoglubulin therapy
29. Editorial comments: Two clinical viewpoints from Oslo
30. Pathogen inactivation of whole blood and red cell components: An overview of concept, design, developments, criteria of acceptability and storage lesion
31. Blood doping: The flip side of transfusion and transfusion alternatives
32. Anemia treatment of lymphoproliferative malignancies with erypoiesis: An overview of state of the art
33. Editorial comments: Looking for some innovative diagnostic or developmental research studies that might influence our laboratory and clinical decision-making
34. Massive transfusion: An overview of the main characteristics and potential risks associated with substances used for correction of a coagulopathy
35. Editorial commentary
36. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates
37. Current debate on pathogen inactivation of platelet concentrates – To use or not to use?
38. Editorial commentary – A snapshot on the role of newer technologies identifying variability in donor red cell storage stability and its implications on recipients' clinical outcome
39. The relationship of anti-HPA-1a amount to severity of neonatal alloimmune thrombocytopenia – Where does it stand?
40. What’s happening CAR T cell immunotherapy
41. An invite for evidence-based insights and expert viewpoints on blood donor recruitment and retention
42. The six questions of pathogen reduction technology: An overview of current opinions
43. Updates on pathogen inactivation of plasma using Theraflex methylene blue system
44. What's happening editorial commentary: Immunological impacts CD71+RBC subpopoulation present in stored blood and validation of a new irradiation system for off-line EPC
45. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: Current status/future trends
46. Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events
47. Pathogen-reduction systems for blood components: The current position and future trends
48. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
49. The combined effect of platelet storage media and intercept pathogen reduction technology on platelet activation/activability and cellular apoptosis/necrosis: Lisbon-RBS experience
50. International forum – The “6 Pillars” of best practice in apheresis technologies: Introductory remarks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.